SCHEMBL5714947

SCHEMBL5714947

O=C(Oc1ccc(Cc2ccc(C(F)(F)F)cc2)cc1)N1CCN(c2ccc(F)cn2)CC1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.56
HPGD P15428 1/20 0.56
TRPV1 Q8NER1 2/20 0.53
TRPA1 O75762 1/20 0.52
PRKAA2 P54646 1/20 0.51
KDM4E B2RXH2 3/20 0.48
PKM P14618 1/20 0.48
HRH3 Q9Y5N1 2/20 0.48
LIPE Q05469 3/20 0.47
LMNA P02545 1/20 0.47
BCHE P06276 1/20 0.47
SMO Q99835 1/20 0.46
PANK3 Q9H999 1/20 0.46
MEN1 O00255 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
KMT2A Q03164 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714721 0.93 SMN1; SMN2 (0.65) SMN1; SMN2HPGDTRPV1TRPA1KDM4E
SCHEMBL5715100 0.91 SMN1; SMN2 (0.57) SMN1; SMN2HPGDTRPV1PRKAA2KDM4E
SCHEMBL5715657 0.89 TRPA1 (0.56) SMN1; SMN2HPGDTRPV1TRPA1PRKAA2
SCHEMBL5715468 0.89 SMN1; SMN2 (0.61) SMN1; SMN2HPGDTRPV1TRPA1PRKAA2
SCHEMBL5714889 0.88 SMN1; SMN2 (0.54) SMN1; SMN2HPGDTRPV1TRPA1PRKAA2
SCHEMBL5714945 0.88 SMN1; SMN2 (0.54) SMN1; SMN2HPGDTRPV1TRPA1PRKAA2
SCHEMBL5714727 0.86 SMN1; SMN2 (0.62) SMN1; SMN2HPGDTRPV1TRPA1KDM4E
SCHEMBL5714086 0.84 TRPV1 (0.61) SMN1; SMN2HPGDTRPV1TRPA1BCHE
SCHEMBL5714804 0.84 LIPE (0.70) SMN1; SMN2HPGDKDM4EPKMLIPE
SCHEMBL5714999 0.82 HSD17B10 (0.47) SMN1; SMN2HPGDTRPV1TRPA1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
CN-1798735-A 1-aryl-4- (aryloxycarbonyl) -piperazine derivatives as inhibitors of hormone sensitive lipase NOVO NORDISK AS (DK) 2006-07-05 CN claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
CN-1798735-A 1-aryl-4- (aryloxycarbonyl) -piperazine derivatives as inhibitors of hormone sensitive lipase NOVO NORDISK AS (DK) 2006-07-05 CN disclosed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC SMN1; SMN2 2732/4885HPGD 793/4885TRPV1 1675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.